Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging epigenetic-modulating therapies in lymphoma
David Sermer, Laura Pasqualucci, Hans‐Guido Wendel, et al.
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 8, pp. 494-507
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Enhancers in disease: molecular basis and emerging treatment strategies
Annique Claringbould, Judith B. Zaugg
Trends in Molecular Medicine (2021) Vol. 27, Iss. 11, pp. 1060-1073
Open Access | Times Cited: 147
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George, Sayan Mullick Chowdhury, Amber Hart, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1328-1328
Open Access | Times Cited: 91
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, et al.
Protein & Cell (2020) Vol. 11, Iss. 7, pp. 472-482
Open Access | Times Cited: 81
Genetic and epigenetic determinants of diffuse large B-cell lymphoma
Tanner J. Bakhshi, Philippe T. Georgel
Blood Cancer Journal (2020) Vol. 10, Iss. 12
Open Access | Times Cited: 80
Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance
Saima Usman, Ahmad Jamal, Muy‐Teck Teh, et al.
Frontiers in Oral Health (2021) Vol. 1
Open Access | Times Cited: 75
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 8, pp. 4256-4292
Open Access | Times Cited: 73
Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo
Huapan Fang, Zhaopei Guo, Jie Chen, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 65
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma
Man Chun John, Saber Tadros, Alyssa Bouska, et al.
Haematologica (2021) Vol. 107, Iss. 3, pp. 690-701
Open Access | Times Cited: 58
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Yi-Chen Sun, Jing Han Hong, Zhiqiang Ning, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 45
Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer
Yafang Wang, Yu Lei, Zong-long Hu, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 8
Open Access | Times Cited: 40
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Jing Zhang, Yan Gu, Baoan Chen
Cancer Management and Research (2023) Vol. Volume 15, pp. 245-255
Open Access | Times Cited: 26
Targeting Myc-driven stress addiction in colorectal cancer
Haris Saeed, Brian J. Leibowitz, Lin Zhang, et al.
Drug Resistance Updates (2023) Vol. 69, pp. 100963-100963
Open Access | Times Cited: 23
Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL
Wenxia Bian, Haoran Li, Yuhan Chen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116386-116386
Open Access | Times Cited: 12
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Ping Zhang, Mingzhi Zhang
Clinical Epigenetics (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 69
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Michel Montalvo-Casimiro, Rodrigo González‐Barrios, Marco Antonio Meraz-Rodriguez, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 65
Histone methyltransferase and drug resistance in cancers
Cheng Yang, Jiayu Zhang, Yukui Ma, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 60
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
Maria Florencia Giraudo, Zachary Jackson, Indrani Das, et al.
Pathogens and Immunity (2024) Vol. 9, Iss. 1, pp. 1-17
Open Access | Times Cited: 8
SEDT2/METTL14-mediated m6A methylation awakening contributes to hypoxia-induced pulmonary arterial hypertension in mice
Xueliang Zhou, Feng-Jian Huang, Yang Li, et al.
Aging (2021) Vol. 13, Iss. 5, pp. 7538-7548
Open Access | Times Cited: 41
Ezh2 Inhibition by Tazemetostat: Mechanisms of Action, Safety and Efficacy in Relapsed/refractory Follicular Lymphoma
Edith Julia, Gilles Salles
Future Oncology (2021) Vol. 17, Iss. 17, pp. 2127-2140
Open Access | Times Cited: 35
ALKBH5-mediated N6-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation
Wei Song, Fei Fei, Fengchang Qiao, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Trained immunity: A Yin‐Yang balance
Zhidong Hu, Shuihua Lu, Douglas B. Lowrie, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 27
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
Swaminathan P. Iyer, Auris Huen, Weiyun Z. Ai, et al.
Haematologica (2023)
Open Access | Times Cited: 14
HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T Cell Lymphoma
Jiayan Zhu, Feng Wang, Lining Wang, et al.
Cancer Research (2024) Vol. 84, Iss. 15, pp. 2450-2467
Closed Access | Times Cited: 6
Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies
Mihaela Andreescu
Cureus (2024)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top